![]() ![]() However, the use of these agents is associated with a risk for uncontrollable bleeding episodes that can lead to can cause serious or fatal bleeding. Rivaroxaban and apixaban are Factor Xa inhibitors that promote anticoagulation in situations where blood clotting is unfavourable, such as in deep vein thrombosis and pulmonary embolism. It is marketed as Andexxa for intravenous injection or infusion and is indicated for the reversal of anticoagulation in combination with rivaroxaban and apixaban in cases of life-threatening or uncontrolled bleeding. It was developed by Portola Pharmaceuticals and was approved in in May 2018. Ndexanet alfa is a recombinant human coagulation Factor Xa that promotes blood coagulation. It was developed by Portola Pharmaceuticals. It was approved for medical use in the United States in May 2018. It works by binding to rivaroxaban and apixaban. Severe side effects may include blood clots, heart attacks, strokes, or cardiac arrest. Ĭommon side effects include pneumonia and urinary tract infections. It has not been found to be useful for other factor Xa inhibitors. Anticoagulant reversal (factor Xa inhibitors)Īndexanet alfa, sold under the trade name Andexxa among others, is an antidote for the medications rivaroxaban and apixaban, when reversal of anticoagulation is needed due to uncontrolled bleeding. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |